全文获取类型
| 收费全文 | 2456738篇 |
| 免费 | 184259篇 |
| 国内免费 | 4323篇 |
专业分类
| 耳鼻咽喉 | 35380篇 |
| 儿科学 | 74525篇 |
| 妇产科学 | 64694篇 |
| 基础医学 | 344155篇 |
| 口腔科学 | 69551篇 |
| 临床医学 | 220280篇 |
| 内科学 | 484059篇 |
| 皮肤病学 | 49966篇 |
| 神经病学 | 206413篇 |
| 特种医学 | 97261篇 |
| 外国民族医学 | 886篇 |
| 外科学 | 367872篇 |
| 综合类 | 56567篇 |
| 现状与发展 | 1篇 |
| 一般理论 | 998篇 |
| 预防医学 | 198717篇 |
| 眼科学 | 57002篇 |
| 药学 | 182722篇 |
| 61篇 | |
| 中国医学 | 4583篇 |
| 肿瘤学 | 129627篇 |
出版年
| 2019年 | 19441篇 |
| 2018年 | 26745篇 |
| 2017年 | 20335篇 |
| 2016年 | 22121篇 |
| 2015年 | 24933篇 |
| 2014年 | 35342篇 |
| 2013年 | 53615篇 |
| 2012年 | 73531篇 |
| 2011年 | 77056篇 |
| 2010年 | 44941篇 |
| 2009年 | 42688篇 |
| 2008年 | 72563篇 |
| 2007年 | 77071篇 |
| 2006年 | 77697篇 |
| 2005年 | 75748篇 |
| 2004年 | 72728篇 |
| 2003年 | 70052篇 |
| 2002年 | 69135篇 |
| 2001年 | 113587篇 |
| 2000年 | 117706篇 |
| 1999年 | 99280篇 |
| 1998年 | 28100篇 |
| 1997年 | 25664篇 |
| 1996年 | 25604篇 |
| 1995年 | 24722篇 |
| 1994年 | 23260篇 |
| 1993年 | 21642篇 |
| 1992年 | 79862篇 |
| 1991年 | 76901篇 |
| 1990年 | 74055篇 |
| 1989年 | 71293篇 |
| 1988年 | 66241篇 |
| 1987年 | 65210篇 |
| 1986年 | 61743篇 |
| 1985年 | 58797篇 |
| 1984年 | 44518篇 |
| 1983年 | 37916篇 |
| 1982年 | 22984篇 |
| 1981年 | 20441篇 |
| 1979年 | 41647篇 |
| 1978年 | 29193篇 |
| 1977年 | 24526篇 |
| 1976年 | 23002篇 |
| 1975年 | 24159篇 |
| 1974年 | 29965篇 |
| 1973年 | 28347篇 |
| 1972年 | 26496篇 |
| 1971年 | 24389篇 |
| 1970年 | 23048篇 |
| 1969年 | 21360篇 |
排序方式： 共有10000条查询结果，搜索用时 31 毫秒
71.
Andrew J Lindford Heikki Mäkisalo Hannu Jalanko Jouni Lauronen Veli-Jukka Anttila Susanna Juteau Antti-Jussi Ämmälä Anna Eskola Samuli Saarni Helena Isoniemi Antti Mäkitie Patrik Lassus 《Journal of plastic, reconstructive & aesthetic surgery》2019,72(2):173-180
Aim
We herein describe the establishment of the Helsinki Vascularized Composite Allotransplantation (VCA) program and its execution in the first two face transplant cases.Methods & patients
The Helsinki VCA program initially required the fulfillment of legal, hospital, financial, and ethical requirements. Thereafter, the assembling of a multidisciplinary team commenced. A team of Plastic, maxillofacial and ENT surgeons comprise the facial VCA team. The protocol involves collaboration with the Solid Organ Transplant (SOT) team, transplant immunology, immunosuppression, microbiology, psychiatric evaluation, well-defined VCA indications and informed consent. Between 2011 and 2017 two patients were selected for transplantation. Both patients had a severe composite facial deformity involving the maxilla and mandible following earlier ballistic injury.Results
Patient 1 was a 35 year-old male who underwent successful near total face transplantation in February 2016 and at 30 months he has a good aesthetic outcome with symmetrical restoration of the central face and good sensory and symmetrical motor functional outcomes. Patient 2 was a 58 year-old male who underwent full face transplantation in March 2018 and at 5 months he has recovered without major problems.Conclusion
A successful facial VCA program requires a well-prepared research protocol, experts from multiple specialties and careful patient selection. The establishment of the Helsinki VCA program required long and thorough planning and resulted in the first two Nordic face transplantation cases. This protocol now forms the platform (as a proof of concept) for other types of vascularized composite allotransplantations. 相似文献72.
73.
K.A. Lee M.T.A. Sharabiani D. Tumino J. Wadsley V. Gill G. Gerrard R. Sindhu M.N. Gaze L. Moss K. Newbold 《Clinical oncology (Royal College of Radiologists (Great Britain))》2019,31(6):385-390
Aims
To obtain an overview of the management and outcomes of children aged 18 years or younger diagnosed with differentiated thyroid carcinoma of follicular cell origin across the UK, by collecting and analysing data from the limited number of centres treating these patients. This multicentre data might provide a more realistic perspective than single-institution series.Materials and methods
Six centres submitted data extracted from historical records on patients aged 18 years or younger, diagnosed between 1964 and 2017. The univariate and multivariable Cox proportional hazard model was used to identify potential predictors of progression-free survival, using national data as a control.Results
Data on 166 patients were available for analysis. Females (74%) were predominant, and the age ranged from 3 to 19 years at diagnosis, mean 14.1 years. Nodal metastases were present in 51%; 12% had distant metastases. After surgery, 95% received radioactive iodine (39% on more than one occasion) and 4% received external beam radiotherapy. With a median follow-up duration of 5 years, 69% are alive with no evidence of disease; 20% are alive with a raised thyroglobulin level as the only evidence of residual disease; 6% have residual structural disease detectable on imaging; 2% have died, from cerebral metastases.Conclusion
Despite most patients having advanced disease at presentation, outcomes are very good. A national prospective registry should allow systematic collection of good-quality data and may facilitate research to further improve outcomes. 相似文献74.
Kamila Pires de Carvalho Mariana Tavares Miranda Lima Fernanda Silva Mazzutti Isis Danyelle Dias Custódio Paula Philbert Lajolo Canto Carlos Eduardo Paiva Yara Cristina de Paiva Maia 《Clinical breast cancer》2019,19(1):e208-e219
Purpose
To study the use of functional capacity (FC) level and duration of aromatase inhibitor (AI) therapy with adiposity parameters in women with breast cancer.Patients and Methods
FC was evaluated through the Health Assessment Questionnaire, which was assessed by classification and divided into 3 groups: G1 = mild to moderate difficulty, G2 = moderate to severe disability, and G3 = severe or very severe disability. Body mass, height, and waist circumference (WC) were measured, and body mass index (BMI) was calculated. Bioelectrical impedance analysis was used to calculate body fat (BF) and fat-free mass. The women were divided into 2 time groups (T1 and T2), which were determined by the median months of AI use (T1 ≤ 29.5 and T2 > 29.5 months).Results
Impaired FC and adiposity parameters were significantly positively correlated. In addition, physical exercise was significantly lower in women assessed as G2 and G3 compared to those assessed as G1. The effect of FC on BMI, BF, and WC was also verified, as was the effect of the duration of AI receipt on BMI and BF. Women at T1 had significantly greater functional disability, BMI, and BF values. In addition, although not statistically significant, women in T1 who were assessed as G3 presented higher BMI, WC, and BF values than those in T2.Conclusion
Adiposity above the recommended parameters and impaired FC were associated with the shortest time of receipt of adjuvant endocrine therapy with AI. 相似文献75.
Edward J.A. Harris Steven Kao Brian McCaughan Takashi Nakano Nobuyuki Kondo Rebecca Hyland Anna K. Nowak Nicholas H. de Klerk Fraser J.H. Brims 《Journal of thoracic oncology》2019,14(2):288-293
Introduction
Malignant pleural mesothelioma (MPM) is an uncommon cancer with a poor prognosis and heterogeneous survival. Surgery for MPM is offered in some specialist centers to highly selected patients. A previously described classification and regression tree (CART) model stratified survival in unselected MPM patients using routinely collected clinical data. This study aimed to examine the performance of this CART model on a highly selected surgical population.Methods
Data were collected from subjects undergoing cytoreductive surgery for MPM from specialist centers in Hyõgo, Japan, and Sydney, Australia, between 1991 and 2016. The CART model was applied using the combination of clinical variables to stratify subjects into risk groups (1 through 4); survival characteristics were then compared.Results
Two hundred eighty-nine cases were included (205 from Australia, 84 from Japan). Overall median survival was 34.6 (interquartile range: 17.5–56.1) months; median age was 63.0 (interquartile range: 57.0–67.8) years, and 83.0% (n = 240) were male. There were no clinically meaningful differences between the two cohorts. Survival across the four risk groups was significantly different (p < 0.0001); the model stratified survival well with a Harrell's concordance statistic of 0.62 (95% confidence interval: 0.57–0.66) at 36 months. The group with the longest survival (median, 82.5 months) had: no weight loss, hemoglobin > 153 g/L and serum albumin > 43 g/L at time of referral to the surgical center.Conclusions
Using routinely available clinical variables, the CART model was able to stratify surgical patients into risk groups with statistically different survival characteristics with fair to good performance. Presence of weight loss, anemia, and low albumin should confer caution when considering surgical therapy for MPM. 相似文献76.
Sabin J. Bozso Jeevan Nagendran Michael W.A. Chu Bob Kiaii Ismail El-Hamamsy Maral Ouzounian Jörg Kempfert Christoph Starck Michael C. Moon 《The Annals of thoracic surgery》2021,111(2):463-470
- Download : Download high-res image (134KB)
- Download : Download full-size image
77.
78.
Gregory Lazarian Shanye Yin Elisa ten Hacken Tomasz Sewastianik Mohamed Uduman Alba Font-Tello Satyen H. Gohil Shuqiang Li Ekaterina Kim Heather Joyal Leah Billington Elizabeth Witten Mei Zheng Teddy Huang Mariano Severgnini Valerie Lefebvre Laura Z. Rassenti Catherine Gutierrez Catherine J. Wu 《Cancer cell》2021,39(3):380-393.e8
- Download : Download high-res image (201KB)
- Download : Download full-size image
79.
Dae Won Kim Elaine Tan Jun-Min Zhou Michael J. Schell Maria Martinez James Yu Estrella Carballido Rutika Mehta Jonathan Strosberg Iman Imanirad Richard D. Kim 《British journal of cancer》2021,124(11):1803
Background MMR proficient (pMMR) colorectal cancer (CRC) is usually unresponsive to immunotherapy. Recent data suggest that ibrutinib may enhance the anti-tumour activity of anti-PD-1 immunotherapy. In this study, we evaluated the safety and efficacy of ibrutinib plus pembrolizumab in refractory metastatic CRC.Methods This was a phase 1/2 study in patients with refractory metastatic pMMR CRC. The primary endpoints for phases 1 and 2 were maximum tolerated dose (MTD) and disease control rate, respectively. The secondary endpoints were safety, progression-free survival (PFS) and overall survival (OS).Results A total of 40 patients were enrolled. No dose-limiting toxicity was observed, and MTD was not identified. The highest tested dose of ibrutinib, 560 mg once daily, was combined with a fixed dose of pembrolizumab 200 mg every 3 weeks for the phase 2 portion. The most common grade 3/4 treatment-related adverse events were anaemia (21%), fatigue (8%) and elevated alkaline phosphatase (8%). Among 31 evaluable patients, 8 (26%) achieved stable disease, and no objective response was observed. The median PFS and OS were 1.4 and 6.6 months, respectively.Conclusion Ibrutinib 560 mg daily plus pembrolizumab 200 mg every 3 weeks appears to be well tolerated with limited anti-cancer activity in metastatic CRC.ClinicalTrials.gov identifier NCT03332498.Subject terms: Cancer immunotherapy, Colorectal cancer 相似文献
80.
Sarah J. Schrauben Haochang Shou Xiaoming Zhang Amanda Hyre Anderson Joseph V. Bonventre Jing Chen Steven Coca Susan L. Furth Jason H. Greenberg Orlando M. Gutierrez Joachim H. Ix James P. Lash Chirag R. Parikh Casey M. Rebholz Venkata Sabbisetti Mark J. Sarnak Michael G. Shlipak Sushrut S. Waikar Paul L. Kimmel Ramachandran S. Vasan Harold I. Feldman Jeffrey R. Schelling 《Journal of the American Society of Nephrology : JASN》2021,32(1):115